Pharma BD Deal Intelligence

Grifols SA / Talecris Biotherapeutics Holdings Corp.

2010 · Acquisition/Merger · $3.4B · Complete

Announcement Sentiment

Strongly positive

Grifols agreed to acquire Talecris for ~$3.4B (cash + non-voting shares: $19 cash + 0.641 Grifols share = $26.16/share, 53% premium). Created leading global plasma protein company. Closed June 2011 after FTC divestitures.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jun 07, 2010
Closed Jun 01, 2011
Deal value $3.4B
Deal type Acquisition/Merger
Therapeutic area Immune deficiencies; bleeding disorders
Indications Immune deficiencies; bleeding disorders
Key assets Plasma-derived therapies (IVIG, albumin, alpha-1 antitrypsin)
Mechanism Plasma protein replacement therapies

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals